The incidence of all-cause blindness was less often coded for individuals with GLP-1 RA prescriptions compared with those without GLP-1 RA prescriptions (2313 [1.2%] vs 3051 [1.6%] events; HR, 0.77 [95% CI, 0.73-0.82]; P < .001), a 24.2% relative reduction in the risk of blindness. Here, GLP1R is linked to blindness (disorder).